Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Assets (2017 - 2025)

Sutro Biopharma's Non-Current Assets history spans 9 years, with the latest figure at $27.5 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 40.19% year-over-year to $27.5 million; the TTM value through Sep 2025 reached $136.2 million, down 28.18%, while the annual FY2024 figure was $43.9 million, 10.77% down from the prior year.
  • Non-Current Assets for Q3 2025 was $27.5 million at Sutro Biopharma, down from $30.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $122.9 million in Q4 2021 and bottomed at $27.5 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $52.9 million (2023), against an average of $59.9 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 708.24% in 2021 before it crashed 56.23% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $122.9 million in 2021, then tumbled by 56.23% to $53.8 million in 2022, then dropped by 8.55% to $49.2 million in 2023, then dropped by 10.77% to $43.9 million in 2024, then tumbled by 37.25% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Non-Current Assets are $27.5 million (Q3 2025), $30.7 million (Q2 2025), and $34.0 million (Q1 2025).